此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines

2011年8月2日 更新者:Merz Pharmaceuticals GmbH

A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Determine the Optimal Dose of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

NT 201 is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, NT 201 causes local weakening to full paralysis depending on the administered dose. Botulinum toxin type A is widely used for aesthetic treatment of facial lines. This study will determine the optimal dose of NT 201 in the treatment of glabellar frown lines.

研究概览

研究类型

介入性

注册 (实际的)

191

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Frankfurt、德国、60318
        • Merz Pharmaceuticals GmbH

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Moderate to severe glabellar frown lines

Exclusion Criteria:

  • Previous insertion of permanent material in the glabellar area
  • Neuromuscular function disease

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂
Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
实验性的:20 U NT 201
Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
其他名称:
  • incobotulinumtoxinA (Xeomin)
  • BTX-A,
  • BoNT/A,
实验性的:10 U NT 201
Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
其他名称:
  • incobotulinumtoxinA (Xeomin)
  • BTX-A,
  • BoNT/A,
实验性的:30 U NT 201
Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
其他名称:
  • incobotulinumtoxinA (Xeomin)
  • BTX-A,
  • BoNT/A,

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of responders at maximum frown at Day 30 as assessed by the investigator according to Facial Wrinkle Scale (FWS)
大体时间:Baseline (Day 0) to Day 30

Responders on the FWS are defined as subjects with glabellar line severity of none (0) or mild (1).

The Primary Analysis Set (PAS) will be used for all confirmatory tests for the primary efficacy variables of the co-primary endpoint. The PAS will consist of all subjects in the Full Analysis Set who have available assessments by the investigator for severity of glabellar frown lines at maximum frown on Day 30, as well as patient's assessment at Day 0 and Day 30. All analyses for this population will therefore use the same sample for both primary endpoints.

Baseline (Day 0) to Day 30
Percentage of responders at maximum frown at Day 30 as assessed by patient's assessment according to 4-point scale
大体时间:Baseline (Day 0) to Day 30

Responders will be subjects with at least a 1-point improvement compared to Day 0.

The Primary Analysis Set (PAS) will be used for all confirmatory tests for the primary efficacy variables of the co-primary endpoint. The PAS will consist of all subjects in the Full Analysis Set who have available assessments by the investigator for severity of glabellar frown lines at maximum frown on Day 30, as well as patient's assessment at Day 0 and Day 30. All analyses for this population will therefore use the same sample for both primary endpoints.

Baseline (Day 0) to Day 30

次要结果测量

结果测量
措施说明
大体时间
Percentage of responders at maximum frown at Day 90 as assessed by the investigator according to FWS
大体时间:Baseline (Day 0) to Day 90

Responders on the FWS are defined as subjects with glabellar line severity of none (0) or mild (1).

Secondary efficacy endpoints will be analyzed analogously to the analysis of primary efficacy endpoint.

Baseline (Day 0) to Day 90
Percentage of responders at maximum frown at Day 90 as assessed by patient's assessment
大体时间:Baseline (Day 0) to Day 90

Responders will be subjects with at least a 1-point improvement compared to Day 0.

Secondary efficacy endpoints will be analyzed analogously to the analysis of primary efficacy endpoint.

Baseline (Day 0) to Day 90

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Merz Pharmaceuticals、Merz Pharmaceuticals GmbH

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2006年11月1日

研究完成 (实际的)

2007年8月1日

研究注册日期

首次提交

2007年2月1日

首先提交符合 QC 标准的

2007年2月1日

首次发布 (估计)

2007年2月2日

研究记录更新

最后更新发布 (估计)

2011年8月3日

上次提交的符合 QC 标准的更新

2011年8月2日

最后验证

2011年8月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅